Esperion Therapeutics, Inc.
ESPR
$2.51
-$0.21-7.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 168.45M | 87.31M | 82.39M | 65.00M | 69.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 168.45M | 87.31M | 82.39M | 65.00M | 69.11M |
| Cost of Revenue | 41.78M | 55.42M | 35.78M | 44.10M | 36.61M |
| Gross Profit | 126.67M | 31.89M | 46.60M | 20.90M | 32.51M |
| SG&A Expenses | 41.43M | 41.85M | 39.51M | 43.00M | 36.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.21M | 97.27M | 75.29M | 87.09M | 73.53M |
| Operating Income | 85.23M | -9.96M | 7.10M | -22.10M | -4.42M |
| Income Before Tax | 63.67M | -31.33M | -12.73M | -40.46M | -21.32M |
| Income Tax Expenses | 1.84M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.83M | -31.33M | -12.73M | -40.46M | -21.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.83M | -31.33M | -12.73M | -40.46M | -21.32M |
| EBIT | 85.23M | -9.96M | 7.10M | -22.10M | -4.42M |
| EBITDA | 85.26M | -9.93M | 7.12M | -22.07M | -4.39M |
| EPS Basic | 0.26 | -0.16 | -0.06 | -0.21 | -0.11 |
| Normalized Basic EPS | 0.17 | -0.10 | -0.04 | -0.13 | -0.06 |
| EPS Diluted | 0.22 | -0.16 | -0.06 | -0.21 | -0.11 |
| Normalized Diluted EPS | 0.14 | -0.10 | -0.04 | -0.13 | -0.06 |
| Average Basic Shares Outstanding | 236.68M | 200.74M | 197.55M | 196.13M | 195.57M |
| Average Diluted Shares Outstanding | 284.57M | 200.74M | 197.55M | 196.13M | 195.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |